BACKGROUND: Disease-specific patient-reported outcome (PRO) instruments are important in assessing the impact of disease and treatment. The Pulmonary Arterial HypertensionSymptoms and Impact Questionnaire is the first instrument for quantifying pulmonary arterial hypertension (PAH) symptoms and impacts developed according to the 2009 US Food and Drug Administration PRO guidance; previous qualitative research in patients with PAH supported its initial content validity.
Pulmonary arterial hypertension (PAH) is a rare and debilitating chronic disease of the pulmonary vasculature, characterized by vascular proliferation and remodeling of the small pulmonary arteries, which ultimately leads to right heart failure and death. 1, 2 Typical symptoms (including shortness of breath, fatigue, chest pain, and lightheadedness) 1, 3 have a major impact on patients' functioning and physical, psychological, and social well-being. 4, 5 Because symptom experience is subjective, patientreported outcome (PRO) instruments are needed to evaluate the effect of both PAH and its treatments on symptoms and the impact of symptoms on patients' lives. 4 Recommendations for PAH trial endpoints now stress the importance of measuring PROs as a secondary endpoint in clinical trials, in addition to clinical endpoints such as change in exercise capacity, cardiac hemodynamic variables, and composite endpoints with morbidity and mortality. 6, 7 In 2009, the US Food and Drug Administration (FDA) published a PRO guidance for industry outlining recommended steps for the development of a PRO. 8 Although a number of PRO instruments have previously been developed for and/or used in patients with PAH, 9-12 none of these was developed explicitly according to the FDA PRO guidance. The present article describes the first PRO instrument for use with patients with PAH developed strictly following this guidance, ensuring that items are relevant and meaningful to these patients.
With the objective of developing a PRO measure that can be used both in clinical trials and in clinical practice, a draft version of the Pulmonary Arterial HypertensionSymptoms and Impact (PAH-SYMPACT) questionnaire was developed based on qualitative interviews with patients with PAH. 13 The development of this questionnaire-which consists of two parts (one assessing PAH symptoms and the other assessing impacts)-has previously been described (Fig 1) . 13 Here, we report results of the psychometric analyses performed to validate the PAH-SYMPACT based on A Study of Macitentan in Pulmonary Arterial Hypertension to Validate the PAH-SYMPACT (SYMPHONY). This psychometric validation study included patients with PAH who received macitentan 10 mg, an endothelin receptor antagonist approved for the treatment of PAH, 14, 15 to enable change in symptoms and impacts. The objectives of the present study were to finalize the item content and domain structure of the PAH-SYMPACT and to show content validity of the final questionnaire, as well as to assess its psychometric properties (including sensitivity to change).
Materials and Methods

Study Design
SYMPHONY was a prospective, open-label, single-arm, multicenter, Phase IIIb study in patients with PAH receiving macitentan 10 mg once daily. The study was conducted by Evidera in collaboration with the sponsor and a Steering Committee comprising eight expert clinicians from the United States experienced in treating patients with PAH.
The present study was conducted in accordance with the amended Declaration of Helsinki. Local institutional review boards or independent ethics committees at each participating institution approved the protocol (e -Table 1) , and all patients provided written informed consent.
Pulmonary Hypertension: idiopathic PAH, heritable PAH, or PAH associated with drug or toxin exposure, with HIV infection, with connective tissue disease, or with repaired simple congenital systemic-to-pulmonary shunts. 16 Confirmation of the diagnosis by using right-heart catheterization was required.
Patients were required to be in functional class (FC) II to IV, according to the World Health Organization classification, and to have a 6-min walk distance (6MWD) of at least 150 m. Patients receiving a phosphodiesterase type-5 inhibitor or inhaled prostacyclin were required to have been receiving stable doses for at least 3 months. Patients had to be able to speak and read English.
Assessments
Following screening, patients had a 2-week baseline period followed by a 16-week period of macitentan treatment (Fig 2) 13 an electronic version of the PAH-SYMPACT (ePRO) 13 using a tablet computer during four study periods (ePRO 1-4). The draft PAH-SYMPACT comprised a yes/no question about oxygen use (assessed daily for 1 week), 16 symptom items with a 24-h recall period (assessed daily for 1 week), and 25 questions about impacts experienced during the past 7 days (assessed on the last day of the week). Each PAH-SYMPACT symptom or impact item was scored by using a 5-point Likert scale.
Health-related quality of life (HRQoL), 6MWD, World Health Organization FC, and clinician-and patient-reported disease severity were assessed at screening, baseline, and weeks 8 and 16. HRQoL was assessed by using the 36-item Medical Outcomes Study Short Form Survey (SF-36 v2) 17 and the Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR) 10 questionnaire. Disease severity was measured by using the Clinician Global Impression of Severity (CGI-S) and the Patient Global Assessment of Disease Severity (PGA-S), with a Likert scale ranging from 1 (none) to 6 (very severe). Clinician-reported impression of change in disease severity was also evaluated at weeks 8 and 16 by using the Clinician Global Impression of Change (CGI-C), with a Likert scale ranging from -3 (very much worse) to 3 (very much better).
Item Reduction and Content Validation
Analyses were conducted to support finalization of item content and domain structure of the PAH-SYMPACT and to confirm its content validity; namely, to show that it measures symptoms and impacts that are important to patients, without redundancy (ie, without measuring the same concept more than once).
Distributional characteristics of each of the items were evaluated to test for floor and ceiling effects (ie, the clustering of item scores at the bottom or the top of the response-scale range) that could render the questionnaire unresponsive or insensitive to change, or make it inappropriate for a broad range of patients. Pairwise item-to-item correlations were performed to identify questions measuring the same concept (correlation $ 0.7 indicating potential redundancy). 18 Rasch analysis was undertaken to identify items that did not fit the scoring assumptions 19 (ie, responses did not align with patient-specific severity as expected). Factor analyses were performed to assign items to domains; initially, exploratory factor analysis was conducted to identify the underlying relationships between individual items. 20 The exploratory factor analysis was conducted simultaneously with the Rasch analysis to allow identification and examination of items with poor fit (ie, disordered thresholds); these items were flagged for potential deletion. Initial rounds of exploratory factor analysis were set to include three factors for both symptoms and impacts, and were followed by exploration of two-and four-factor solutions.
Items that had high floor or ceiling effects or high correlations with other items, were misfitting, or had factor loadings < 0.3 (ie, the weight or correlation explaining the relationship between each item and the underlying factor/domain) were flagged for further assessment. The final decision regarding item inclusion or exclusion was based on the previous qualitative research, the psychometric analyses (including the exploratory factor analysis and Rasch analyses), and input from the Steering Committee. Confirmatory factor analysis was performed on the final item content, and the conceptual framework was finalized. 20 All psychometric analyses were performed in accordance with the FDA guidance. chestjournal.org
An analysis of differential item functioning was performed to determine whether performance of the PAH-SYMPACT differs in patients with oxygen use vs those without oxygen use.
Psychometric Validation
Internal consistency reliability analysis was performed to assess how well items fit in their hypothesized domains, using data from ePRO period 2. Cronbach's alpha $ 0.70 and $ 0.80 indicate good and excellent fit, respectively.
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Test-retest reliability analysis assessed the stability of PAH-SYMPACT domain scores between ePRO periods 1 and 2 (ie, the two baseline PAH-SYMPACT assessment periods, from week -2 to week -1 and from week -1 to week 0, respectively) in patients who remained stable between visits 1 and 2 (ie, the screening visit between week -4 and week -2 and the baseline visit at week 0) based on the PGA-S. An intraclass correlation coefficient $ 0.70 demonstrates good testretest reliability. Known-groups validity (ie, the ability of domain scores to distinguish between patient groups that differ by key indicators) was tested with 1-way ANOVA using Scheffé post hoc comparisons on domain scores from ePRO period 2 vs scores from visit 2 for FC, PGA-S, and CGI-S.
The sensitivity to change of the PAH-SYMPACT (ie, the extent to which the domain scores reflect change in the patient's condition) was evaluated by using ANOVA, with change from visit 2 to visit 4 in PGA-S, CGI-S, and CGI-C scores as the independent variables; change from ePRO period 2 to period 4 in domain score was the dependent variable.
Results
Patients
Between April 2013 and October 2015, a total of 284 patients with PAH were enrolled at 71 centers across the United States. Six patients were excluded from the analysis because of protocol deviations (Fig 1) . The 278 patients included in the analyses were generally representative of the PAH population seen in clinical practice 22 (Table 1) . Overall, 46% were receiving background PAH-specific therapy.
Item Reduction and Content Validation
Item Performance Analysis: Across symptom and impact items, ceiling effects were negligible, but floor effects were evident (Table 2) , likely reflecting the mild to moderately severe population enrolled in SYMPHONY, many of whom were receiving PAH treatment at baseline. Substantial floor effects (> 50% of patients) were observed for three symptom items and four impact items. All but one symptom item (loss of appetite) and one impact item (maintain relationships) had high correlations ($ 0.70) with at least one other item measuring similar concepts, indicating potential redundancy.
Evaluation of the rating scale structure (based on Rasch analysis) indicated disordering of responses for four symptom items and seven impact items (Table 2) .
Item Reduction and Exploratory Factor Analysis:
Based on the item performance analyses, input from the Steering Committee, and the previous qualitative research, five symptom items and 14 impact items were removed (Table 3) , leaving 11 symptom items and 11 impact items. Exploratory factor analysis identified two symptom domains and two impact domains. oxygen (data not shown), indicating that the PAH-SYMPACT can be scored the same way irrespective of oxygen use.
Confirmatory Factor Analysis:
Confirmatory factor analysis showed acceptable model fit for symptom items (comparative fit index ¼ 0.861) and good model fit for impact items (comparative fit index ¼ 0.960). The two symptom domains were labeled Cardiopulmonary Symptoms and Cardiovascular Symptoms, and the two impact domains were labeled Physical Impacts and Cognitive/Emotional Impacts (Fig 3) . The mean coefficients of determination for these domains were 0.43, 0.50, 0.63, and 0.64, respectively. 
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Factor loadings for all items (e-Tables 3 and 4) exceeded the acceptable fit threshold of 0.3 except for "swelling in ankles or legs" (0.297). This item was retained on the advice of all eight clinical experts of the Steering Committee because they identified this item to be a key cardiopulmonary symptom that is highly relevant to patients with severe PAH.
Psychometric Characteristics
Reliability: Internal consistency reliability was high for all four domains (ie, Cronbach's alpha > 0.80) ( Table 4 ), indicating that the items are appropriately placed within their domains.
Domain scores were highly consistent in patients with stable disease, demonstrating high reproducibility of scores for all four domains in the test-retest reliability analysis (intraclass correlation coefficient: 0.84-0.94) ( Table 5 ).
Construct and Known-Groups Validity: PAH-SYMPACT domain scores correlated with those of generic and PH-specific HRQoL questionnaires (Table 6) , with correlations highest for measures of similar constructs (concurrent validity). Within this study population, the internal consistency reliability for the two multi-item HRQoL questionnaires used to test construct validity of the PAH-SYMPACT (CAMPHOR and SF-36) was acceptable (e -Tables 5 and 6 ).
Correlations between PAH-SYMPACT Physical Impacts domain scores and 6MWD were highest (r ¼ -0.57; P < .0001), demonstrating the ability of this domain to assess physical functioning. Correlations between other domain scores and 6MWD were low to moderate, confirming that these domains reveal patient-relevant information about symptoms and impacts not captured by exercise capacity.
The questionnaire differentiated well between patients with different baseline disease severity levels (FC II vs III/IV) (Fig 4) and between patient groups on the basis of baseline PGA-S (Table 7) and CGI-S (overall F test, P ¼ .0039 for Cardiovascular Symptoms, P < .0001 for the three other domains) (e- Table 7 ).
Sensitivity to Change: Domain scores were sensitive to improvement in patient-reported disease severity, with significant associations between improvements in PAH-SYMPACT domain scores and improvements in PGA-S scores from baseline to week 16 ( Fig 5) . Domain scores were also sensitive to improvement in clinician-reported disease severity as measured by improvement in CGI-S scores from baseline to week 16 (P < .0001 for all domains except Cognitive/Emotional Impacts, P ¼ .0061), and CGI-C scores from baseline to week 16 (P < .01 for all domains except Cognitive/Emotional Impacts, P ¼ .0665).
Discussion
The final PAH-SYMPACT is a valid and reliable instrument that is sensitive to improvement. The Cronbach's alpha $ 0.70 is considered good; $ 0.80 is considered excellent. questionnaire measures important, patient-relevant aspects of PAH symptoms (which are a direct consequence of the disease) and impacts (which are a consequence of the symptoms) that are not captured by other clinical endpoints (eg, change in exercise capacity).
Recall periods are clearly defined and align with relevant time frames for assessment; that is, daily recall for symptoms, which may vary from day to day, vs weekly recall for impacts, which may not be experienced every day. With 11 symptom items and 11 impact items (plus one item on oxygen use), this brief questionnaire is easy to apply in clinical practice and PAH trials. To ensure its suitability as an efficacy endpoint in future PAH clinical trials, its development has rigorously followed the FDA PRO guidance from the outset, including being based on patient input using patients' language, with input from clinical experts throughout its development. 8 In contrast, the development of other PH-specific PRO instruments has followed different approaches to meet specific needs. For example, the emPHasis-10 was developed primarily as a short, simple scoring system for HRQoL in patients with PH in clinical practice; it is Pairwise comparisons between least squares means were performed by using the Scheffé test, adjusting for multiple comparisons; only statistically significant pairwise comparisons are shown. *P < .05. **P < .001. ***P < .0001. See Figure 1 and 2 legends for expansion of abbreviations.
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CAMPHOR differs from the PAH-SYMPACT in being developed on the theoretical basis of the needs-based model of quality of life, 23 rather than a measure of symptoms and impacts. 24, 25 Measures of internal consistency reliability found in this study for CAMPHOR were high and similar to those reported in the original CAMPHOR development study, which included patients with PAH in the validation population. 10 However, CAMPHOR has fewer response options than the PAH-SYMPACT (yes/no questions and 3-point Likert scales vs 5-point Likert scales), which could make the instrument less sensitive to change. CAMPHOR poses a higher patient burden to complete (it has 65 items), which may make it less practical for use in clinical practice than in clinical trials.
Development populations for the CAMPHOR and the emPHasis-10 included patients with PAH and other forms of PH, primarily chronic thromboembolic PH. 10, 11 Although all forms of PH share symptoms in common, 26 there may be differences between types of PH in the relative importance of symptoms and their effects on patients, 27 and potentially also in the types of symptoms. In contrast, the development of the Living With Pulmonary Hypertension questionnaire, an adaptation of the Minnesota Living With Heart Failure Questionnaire 9 for use in populations with PAH, 12 was based on interviews of patients with PAH exclusively. However, the development process for the Living With Pulmonary Hypertension questionnaire did not incorporate the potential for addition of new symptoms and impacts, and its 1-week recall period for both symptoms and impacts could introduce recall bias for symptoms, given their potential for daily variation.
Substantial floor effects were observed for several PAH-SYMPACT items. This finding was likely attributable (at least in part) to the relatively small number of patients with FC IV as well as the fact that many patients in SYMPHONY were already receiving background PAHspecific therapy, which may have led to a lower symptom burden than would have been seen in untreated patients. Floor effects are unlikely to have an impact on the overall performance of the questionnaire, especially considering that one of the three symptom items and two of the four impact items that had floor effects in > 50% of patients were deleted during item reduction. Those items with floor effects that were retained were of clear importance in PAH, especially for patients with more severe disease, as indicated by the qualitative research and confirmed by the clinical experts.
The main limitations of SYMPHONY include the lack of untreated patients and the fact that few patients had heritable PAH, PAH associated with congenital heart Pairwise comparisons between least squares means were performed by using the Scheffé test, adjusting for multiple comparisons; only statistically significant pairwise comparisons are shown. **P < .001. ***P < .0001. See Figure 2 for definitions of visits and ePRO periods. See Figure 1 and 2 legends for expansion of abbreviations.
chestjournal.org disease or HIV infection, or severe disease (FC IV), reflecting the difficulty of recruiting patients from these less common subgroups. The low number of patients in FC IV in SYMPHONY represents a limitation only in terms of evaluating the psychometric characteristics of the instrument in this subgroup, as the qualitative development of the PAH-SYMPACT included patients in FC IV, 13 and the item content of the questionnaire was designed to cover the full spectrum of symptom severity. A Steering Committee of clinical experts provided input on item retention and removal, taking into account the full spectrum of PAH severity. However, the study did not include a formal method of quantifying the experts' level of agreement on content relevance, such as the Content Validity Index. 28 The absence of a control arm also limits the ability to fully determine the effect of macitentan on PAH symptoms and impacts. Results of analyses of responder/clinically meaningful change thresholds are forthcoming.
Conclusions
The PAH-SYMPACT is a new PAH-specific PRO instrument that contains the symptoms and impacts most relevant from a clinical and patient perspective. The domains have good psychometric properties, including sensitivity to improvement. The questionnaire enhances our ability to assess patient outcomes, following FDA guidance. This questionnaire is now available for use in clinical practice and in clinical trials.
